$SRRK (+2.1% pre) Scholar Rock (SRRK) Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 SMA - SI ooc.bz/l/72951